Last week the British government proposed overturning its ban on the creation of "human-animal embryos."
The draft Human Tissue and Embryos Bill would allow scientists to create a chimeric embryo by injecting cells from an animal into a human embryo and a human transgenic embryo by injecting animal DNA into a human embryo. The first somatic cell nuclear transfers is named after the chimera -- the fire-breathing, three-headed female monster of Greek mythology.
A pre-natal being is not like any other tissue: It is human with its own DNA and, as a human, it has the same fundamental and moral right to life. The proposed therapy based on human embryos is immoral because it forever alters the basic genetic makeup of the person and all his or her future offspring.
Amazingly, although embryonic stem cell experiments have failed to produce a single, unqualified, therapeutic success even in animals, its proponents continue to laud their unproven and unethical methods, ignoring the fact that adult stem-cell therapies are being used extensively today in treating diseases.
We must help those who are suffering, but we must not use a good end to justify evil means. Human beings are not raw materials to be exploited or commodities that can be bought and sold. To suggest otherwise is to endorse a macabre interpretation of progress. This latest method of genetic manipulation is nothing more than Frankenstein science.
Paul Kokoski
Hamilton, Canada
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
The past few months have seen tremendous strides in India’s journey to develop a vibrant semiconductor and electronics ecosystem. The nation’s established prowess in information technology (IT) has earned it much-needed revenue and prestige across the globe. Now, through the convergence of engineering talent, supportive government policies, an expanding market and technologically adaptive entrepreneurship, India is striving to become part of global electronics and semiconductor supply chains. Indian Prime Minister Narendra Modi’s Vision of “Make in India” and “Design in India” has been the guiding force behind the government’s incentive schemes that span skilling, design, fabrication, assembly, testing and packaging, and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry